Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford U-Flourish student wellbeing survey is part of a longitudinal study evaluating the scope of mental health need among undergraduate students. The study aims to better understand what factors determine student mental health and academic outcomes.

The U-Flourish team is a multidisciplinary group of clinicians, academics and students representing a collaboration between the Oxford Student Union, Oxford University Wellbeing and Support Services, the Department of Psychiatry, University of Oxford and Queen's University, Canada.

The transition to university coincides with a critical period in development, characterised by increased autonomy and responsibility, separation from family and support networks, and development of new social connections. At the same time, the brain is undergoing continued development and individuals are at the peak period of risk for the onset of mental illness. University students are also exposed to a number of unique psychosocial stressors relating to creating new friendship groups, sleep disruption and possibly recreational drug use or alcohol binging. 

 

More students are coming to university with different backgrounds, with varied past experiences, with different expectations, and at the same time emergent adulthood is the peak period of risk for onset of psychiatric illness that will persist if untreated and is associated with school failure and drop-out. Add in substance use and it's this kind of perfect storm of all these risk factors hitting a person right at the most vulnerable time in their development.- Professor Anne Duffy, the study's principal investigator.

 

Emerging research emphasises the substantial unmet need for effective care of students, with international data from the World Health Organisation indicating that up to one-fifth of university students suffer from a year-long mental health disorder. Worryingly, these student's mental health disorders were typically untreated and they were more likely to display higher rates of university drop-out. This further highlights the mounting importance for researchers, clinicians and universities to work together to put in place an evidence-based system of mental health care that meets the needs of students.

Read more about U-Flourish.

Similar stories

New Head of the Department of Psychiatry – Professor Belinda Lennox

Professor Belinda Lennox has been welcomed to the role of Head of the Department of Psychiatry at the University of Oxford and will take over leadership in October 2021.

New Transatlantic Partnership in Mental Health

The new partnership between Oxford Health NHS Foundation Trust, the University of Oxford, the University of Toronto, and the Centre for Addiction and Mental Health (CAMH) in Toronto, will enable the development of key structures to facilitate collaboration.

Oxford Awarded Major Funding to Probe Childhood Poverty and Social Inequalities

Ground-breaking multi-disciplinary research is to be launched today by the University of Oxford into the impact of poverty and social inequalities in early childhood, thanks to major funding from the Leverhulme Trust.

David Paterson on the real value of research

Head of DPAG David Paterson joins Lord David Willets, Dame Ottoline Leyser and Priya Guha in discussing the future priorities for UK Research and Innovation (UKRI) - summaries are now published in The Foundation for Science and Technology Journal.

New WA Handley Chair of Psychiatry Appointed

Professor John Geddes has been appointed to the WA Handley Professorship of Psychiatry and will take up this post in November 2021.

Investigating New Treatment for Schizophrenia

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim has been announced to investigate a new drug target for the treatment of schizophrenia.